Locations:

Tag: myelodysplastic syndrome (MDS)

December 19, 2025/Cancer/Blood Cancers

IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

June 10, 2025/Cancer

Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

23-CNR-4044609-CQD-Hero-650×450 AML study

October 20, 2023/Cancer/Research

The Role of Immune Escape in Post-Transplant Leukemia Relapse

Immunological pressure driving genetic mutations

Lab equipment centrifuging blood. Concept image of a blood test.3d rendering.

February 3, 2022/Cancer/Blood Cancers

Newly Identified Risk Factors Help Predict How Aplastic Anemia Can Become Malignant

Study reveals characteristics that may spark the development of myelodysplastic syndrome and acute myeloid leukemia

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

August 31, 2020/Basic & Translational Science

Succession of Molecular Lesions Critical to Leukemia Disease Development

Mutational pattern in MDS is not random, study finds

January 15, 2020/Cancer/Research

New Clinic Tackles Mutations That Increase Risk of Blood Cancers and Heart Disease

CHIP Clinic's goals: Research, preventive care

December 2, 2018/Cancer/Research

The Next Step in Immunotherapy for Myeloid Hematologic Malignancies

Study explores atezolizumab for myelodysplastic syndrome

BackPage 1 of 1Next